



Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

PART I
STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER ENDED JUNE 30, 2015

Sl. No.	Particulars	Rs. in Lakhs			
		3 Months ended 30.06.2015	Preceding 3 months ended 31.03.2015	Corresponding 3 Months ended 30.06.2014 in the previous period	Previous year ended 31.03.2015
		UNAUDITED (1)	UNAUDITED (2)	UNAUDITED (3)	AUDITED (4)
1	Income from operations				
	(a) Net Sales / Income from Operations (Net of excise duty)	20,208.66	24,018.41	18,795.30	86,191.88
	(b) Other Operating Income	1,722.55	2,985.58	1,284.77	6,749.96
	Total Income from operations (net)	21,931.21	27,003.99	20,080.07	92,941.84
2	Expenses				
	(a) Cost of material consumed	10,320.99	12,979.25	10,587.71	47,328.43
	(b) Purchases of stock-in-trade	2,278.01	2,430.01	829.54	4,983.06
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(582.08)	(1,005.45)	(846.10)	(688.13)
	(d) Employee benefit expenses	3,344.71	3,320.25	2,772.98	12,019.75
	(e) Depreciation and amortisation expense	1,373.60	1,348.99	1,080.00	4,925.38
	(f) Other expenses	4,072.40	5,003.67	3,501.47	15,906.44
	Total expenses	20,807.63	24,076.72	17,925.60	84,474.93
3	Profit/(Loss) from Operations before Other Income, finance cost & Exceptional Items (1-2)	1,123.58	2,927.27	2,154.47	8,466.91
4	Other Income	6,845.95	2,007.66	2,547.78	10,017.52
5	Profit/ (Loss) from ordinary activities before finance cost & Exceptional Items (3+4)	7,969.53	4,934.93	4,702.25	18,484.43
6	Finance costs	784.25	923.50	860.86	3,442.27
7	Profit/(Loss) from ordinary activities after finance cost but before Exceptional Items (5-6)	7,185.28	4,011.43	3,841.39	15,042.16
8	Exceptional Items:				
	- Exchange Fluctuation (loss) / gain (Net)	(322.12)	448.52	(55.87)	(462.77)
	- Net (loss) / gain on sale of long term Investments	-	(1,113.29)	-	8,526.77
	- Dividend income from non-current investment in wholly-owned subsidiaries	-	5,624.55	-	45,372.25
	- Merger and restructuring costs (Refer note 6)	(81.10)	(163.37)	-	(1,094.01)
	- Claims on discontinued products	-	-	-	(390.84)
	- Write off of Intangible assets under development and others	-	(90.00)	-	(90.00)
9	Profit / (Loss) from Ordinary Activities before tax (7+ 8)	6,782.06	8,717.84	3,785.52	66,903.56
10	Tax Expense / (credit) (net)	1,979.46	1,751.39	1,105.95	13,671.41
11	Net Profit / (Loss) after tax (9-10)	4,802.60	6,966.45	2,679.57	53,232.15



Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

PART I
STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER ENDED JUNE 30, 2015

	Particulars	3 Months ended 30.06.2015	Preceding 3 months ended 31.03.2015	Corresponding 3 Months ended 30.06.2014 in the previous period	Previous year ended 31.03.2015
		UNAUDITED (1)	UNAUDITED (2)	UNAUDITED (3)	AUDITED (4)
12	Paid-up Equity Share Capital (Face value of Rs.10/-each)	5,962.56	5,961.56	5,956.56	5,961.56
13	Reserves excluding revaluation reserves				141,480.79
14	Earnings per share (face value of Rs. 10/- each) - not annualised				
	(a) Basic EPS (Rs.)	8.06	11.69	4.50	89.36
	(b) Diluted EPS (Rs.)	8.03	11.65	4.49	88.99

PART II
SELECT INFORMATION FOR THE QUARTER ENDED JUNE 30, 2015

		3 Months ended 30.06.2015	Preceding 3 months ended 31.03.2015	Corresponding 3 Months ended 30.06.2014 in the previous period	Previous year ended 31.03.2015
A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding :				
	(a) Number of shares	43,141,419	43,131,419	43,081,419	43,131,419
	(b) Percentage of shareholding	72.35%	72.35%	72.33%	72.35%
2	Promoters and Promoter group shareholding :				
	(a) Pledged / Encumbered				
	- Number of shares	-	-	1,876,667	-
	- Percentage of shareholding (as a % of the total share holding of promoter and promoter group)	0.00%	0.00%	11.38%	0.00%
	- Percentage of shareholding (as a % of the total share capital of the Company)	0.00%	0.00%	3.15%	0.00%
	(b) Non Pledged / Non Encumbered				
	- Number of shares	16,484,202	16,484,202	14,607,535	16,484,202
	- Percentage of shareholding (as a % of the total share holding of promoter and promoter group)	100.00%	100.00%	88.62%	100.00%
	- Percentage of shareholding (as a % of the total share capital of the Company)	27.65%	27.65%	24.52%	27.65%

	Particulars	3 Months ended 30.06.2015
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	0
	Received during the quarter	44
	Disposed of during the quarter	44
	Remaining unresolved at the end of the quarter	0



Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.
STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER ENDED JUNE 30, 2015

Notes:

- 1 The above unaudited results of the Company has been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on July 30, 2015
- 2 The statutory auditors have carried out limited review of the above standalone results.
- 3 The previous period's / year's figures have been regrouped/ reclassified wherever necessary to conform to the classification of the current period.
- 4 During the quarter ended June 30, 2015, 10,000 equity shares were allotted by the Company [under Strides Arcolab ESOP 2011 Scheme] on exercising equal number of options.
- 5 During the quarter, following entities have been incorporated within the Strides Group:
 - a) Strides Arcolab (Australia) Pty Limited incorporated on April 29,2015
 - b) Strides (Australia) Pharma Pty Limited incorporated on May 19, 2015
 - c) Strides (Australia) IP Pty Limited incorporated on May 19, 2015
- 6 The Board of Directors of the Company in their meeting held on September 29, 2014 had approved a Scheme of Amalgamation between the Company and Shasun Pharmaceuticals Limited ("Shasun"). Pursuant to the Scheme of Amalgamation, each equity shareholder of Shasun will be entitled to receive 5 (five) equity shares of the Company in lieu of 16 (sixteen) equity shares held in Shasun.

The appointed date for the Scheme of Amalgamation is April 1, 2015. The approval for the Scheme of Amalgamation has been received from the stock exchanges, the shareholders of both the Companies, the Competition Commission of India and the Hon'ble High Court of Judicature of Madras. The matter is listed for hearing at the Hon'ble High Court of Bombay on August 14, 2015.

Company's application to Foreign Investment Promotion Board (FIPB) in relation to the Scheme of Amalgamation was considered by FIPB at their meeting held on May 28, 2015. Further the Company has been informed vide a letter dated June 18, 2015 issued by the Government of India, Ministry of Finance, Department of Economic Affairs, (FIPB UNIT) ("Letter") that our application has not been approved on the grounds that the Scheme of Amalgamation is yet to be approved by the competent High Courts in India.
- 7 The Company had entered into an agreement with GMS Holdings, ("GMS"), whereby GMS will invest USD 21.90 Million for 25.1% stake in Stelis Biopharma Private Limited ("Stelis"), the biotech arm of the Strides Group, to fund its Greenfield project. The transaction is expected to close in Q2 2015-16 and is subject to customary closing conditions, regulatory and corporate approvals, as may be required.
- 8 Exchange fluctuation gain/loss (net) included under Exceptional Items comprises the exchange gain / loss arising on account of restatement and settlement of long term foreign currency loans and intra-group loans & advances given and gain/ loss on related derivative contracts.
- 9 The Company's operations fall within a single business segment viz. "Pharmaceutical Products" and as such there is no reportable segment information as per Accounting Standard 17 issued under the relevant provisions of the Companies Act, 2013.

For and on behalf of the Board

Arun Kumar
Executive Vice Chairman & Managing Director

Mumbai, July 30, 2015